Veru Inc. (VERU) Buy Target – $2.22 or better

November 26, 2019

Buy Target – $2.22 or better
Sell Target – TradersPro Sell Signal

Veru Inc., an oncology and urology biopharmaceutical company, engages in developing medicines for prostate cancer treatment and prostate cancer supportive care, and urology specialty pharmaceuticals. The company’s commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections; and PREBOOST* 4% benzocaine WIPES for the prevention of premature ejaculation. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies

© Copyright 2020 Investing is Inherently Risky - There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.